Proton magnetic resonance spectroscopy in 22q11 deletion syndrome

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  da Silva Alves, Fabiana ^a   Boot, Erik ^a,b   Schmitz, Nicole ^a   Nederveen, Aart ^a   Vorstman, Jacob ^c   Lavini, Christina ^a   Pouwels, Petra ^d   de Haan, Lieuwe ^a   Linszen, Don ^a   van Amelsvoort, Therese ^a,e  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Ipse de Bruggen   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Arkin Mental Health Care   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; CLOZAPINE; GLUTAMIC ACID; INOSITOL; METHYLPHENIDATE; OLANZAPINE; PROLINE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; BRAIN LEVEL; CHROMOSOME DELETION 22Q11; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; HIPPOCAMPUS; HUMAN; METABOLITE; PREFRONTAL CORTEX; PROTEIN LOCALIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOPATHY; SCHIZOPHRENIA; CASE CONTROL STUDY; FEMALE; MALE; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

22Q11 DELETION SYNDROME; ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; YOUNG ADULT;

EID: 79959705833     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021685     Document Type: Article

References (62)

1. Gothelf D, Schaer M, Eliez S, (2008) Genes, brain development and psychiatric phenotypes in velo-cardio-facial syndrome. Dev Disabil Res Rev 14: 59-68.
2. Botto LD, May K, Fernhoff PM, Correa A, Coleman K, et al. (2003) A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 112: 101-107.
3. Murphy KC, Jones LA, Owen MJ, (1999) High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56: 940-945.
4. Hoogendoorn ML, Vorstman JA, Jalali GR, Selten JP, Sinke RJ, et al. (2008) Prevalence of 22q11.2 deletions in 311 Dutch patients with schizophrenia. Schizophr Res 98: 84-88.
5. Stone LJ, O'Donovan MC, Gurling H, Kirov KG, Blackwood DHR, et al. (2008) Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455: 237-241.
6. Lindsay EA, (2001) Chromosomal microdeletions: dissecting del22q11 syndrome. Nat Rev Genet 2: 858-868.
7. Phang JM, Hu C-A, Valle D, (2001) Disorders of proline and hydroxyproline metabolism pp. 1821-1838.
8. Bender HU, Almashanu S, Steel G, Hu CA, Lin WW, et al. (2005) Functional consequences of PRODH missense mutations. Am J Hum Genet 76: 409-420.
9. Jacquet H, Raux G, Thibaut F, Hecketsweiler B, Houy E, et al. (2002) PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. Hum Mol Genet 11: 2243-2249.
10. Lui H, Heath SC, Sobin C, Roos JL, Galke BL, et al. (2002) Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci USA 99: 3717-3722.
11. Paterlini M, Zakharenko SS, Lai WS, Qin J, Zhang H, et al. (2005) Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci 8: 1586-1594.
12. Raux G, Bumsel E, Hecketsweiler B, van Amelsvoort T, Zinkstok J, et al. (2007) Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome. Hum Mol Genet 16: 83-91.
13. Willis A, Bender HU, Steel G, Valle D, (2008) PRODH variants and risk for schizophrenia. Amino Acids 35: 673-679.
14. Cohen SM, Nadler JV, (1997) Proline-induced inhibition of glutamate release in hippocampal area CA1. Brain Res 769: 333-339.
15. Cohen SM, Nadler JV, (1997) Proline-induced potentiation of glutamate transmission. Brain Res 761: 271-282.
16. Arguello PA, Gogos JA, (2006) Modeling madness in mice: one piece at a time. Neuron 52: 179-196.
17. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
18. Lahti AC, Koffel B, LaPorte D, Tamminga CA, (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9-19.
19. Moghaddam B, (2004) Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 174: 39-44.
20. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, et al. (1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56: 21-27.
21. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH, (2007) Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32: 1888-1902.
22. Burbaeva GS, Boksha IS, Turishcheva MS, Vorobyeva EA, Savushkina OK, et al. (2003) Glutamine synthetase and glutamate dehydrogenase in the prefrontal cortex of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 675-680.
23. Harrison PJ, Weinberger DR, (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10: 40-68.
24. Pilowsky LS, Bressan RA, Stone JM, Erlandsson K, Mulligan RS, et al. (2006) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 11: 118-119.
25. Olney JW, Newcomer JW, Farber NB, (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33: 523-533.
26. Soares DP, Law M, (2009) Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol 64: 12-21.
27. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, et al. (1997) Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 54: 959-965.
28. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, et al. (2002) Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 159: 1944-1946.
29. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, et al. (2003) Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 160: 2231-2233.
30. Goodman BK, Rutberg J, Lin WW, Pulver AE, Thomas GH, (2000) Hyperprolinaemia in patients with deletion (22)(q11.2) syndrome. J Inherit Metab Dis 23: 847-848.
31. Vorstman JA, Turetsky BI, Sijmens-Morcus ME, de Sain MG, Dorland B, et al. (2009) Proline affects brain function in 22q11DS children with the low activity COMT 158 allele. Neuropsychopharmacology 34: 739-746.
32. Kane JM, Leucht S, Carpenter D, Docherty JP, (2003) The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64 (Suppl 12): 5-19.
33. Kay SR, Fiszbein A, Opler LA, (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
34. Canavan AGM, Dunn G, McMillan TM, (1986) Principal components of the WAIS-R. Br J Clin Psychology 25: 81-86.
35. Wechsler D, (1997) WAIS-III: Wechsler Adult Intelligence Scale. Administration and Scoring Manual San Antonio TX: Psychological Corporation.
36. Provencher SW, (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30: 672-679.
37. Stone JM, Day F, Tsagaraki H, Valli I, McLean MA, et al. (2009) Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry 66: 533-539.
38. Kegeles LS, Shungu DC, Anjilvel S, Chan S, Ellis SP, et al. (2000) Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatry Res 98: 163-175.
39. Lutkenhoff ES, van Erp TG, Thomas MA, Therman S, Manninen M, et al. (2008) Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry. In press.
40. Van Elst LT, Valerius G, Buchert M, Thiel T, Rusch N, et al. (2005) Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 58: 724-730.
41. Olbrich HM, Valerius G, Rusch N, Buchert M, Thiel T, et al. (2008) Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry 9: 59-63.
42. Delwing D, Sanna RJ, Wofchuk S, Wyse AT, (2007) Proline promotes decrease in glutamate uptake in slices of cerebral cortex and hippocampus of rats. Life Sci 81: 1645-1650.
43. Catani M, Cherubini A, Howard R, Tarducci R, Pelliccioli GP, et al. (2001) (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 12: 2315-2317.
44. Siger M, Schuff N, Zhu X, Miller BL, Weiner MW, (2009) Regional myo-inositol concentration in mild cognitive impairment Using 1H magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord 23: 57-62.
45. Beacher F, Simmons A, Daly E, Prasher V, Adams C, et al. (2005) Hippocampal myo-inositol and cognitive ability in adults with Down syndrome: an in vivo proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 62: 1360-1365.
46. Irvine RF, Schell MJ, (2001) Back in the water: the return of the inositol phosphates. Nat Rev Mol Cell Biol 2: 327-338.
47. Fisher SK, Novak JE, Agranoff BW, (2002) Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J Neurochem 82: 736-754.
48. Schousboe A, (2003) Role of astrocytes in the maintenance and modulation of glutamatergic and GABAergic neurotransmission. Neurochem Res 28: 347-352.
49. Danbolt NC, (2001) Glutamate uptake. Prog Neurobiol 65: 1-105.
50. Chang L, Friedman J, Ernst T, Zhong K, Tsopelas ND, et al. (2007) Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol Psychiatry 62: 1396-1404.
51. Rusch N, Tebartz van EL, Valerius G, Buchert M, Thiel T, et al. (2008) Neurochemical and structural correlates of executive dysfunction in schizophrenia. Schizophr Res 99: 155-163.
52. Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, et al. (2007) Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res 41: 625-634.
53. Tayoshi S, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, et al. (2009) Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res 108: 69-77.
54. Kates WR, Miller AM, Abdulsabur N, Antshel KM, Conchelos J, et al. (2006) Temporal lobe anatomy and psychiatric symptoms in velocardiofacial syndrome (22q11.2 deletion syndrome). J Am Acad Child Adolesc Psychiatry 45: 587-595.
55. Eliez S, Blasey CM, Schmitt EJ, White CD, Hu D, et al. (2001) Velocardiofacial syndrome: are structural changes in the temporal and mesial temporal regions related to schizophrenia? Am J Psychiatry 158: 447-453.
56. Bloemen OJ, Gleich T, Koning MB, da Silva Alves F, de Haan L, et al. (2011) Hippocampal Glutamate Levels and Striatal Dopamine D(2/3) Receptor Occupancy in Subjects at Ultra High Risk of Psychosis. Biol Psychiatry. In press.
57. Stone JM, Howes OD, Egerton A, Kambeitz J, Allen P, et al. (2010) Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry 68: 599-602.
58. Perneger TV, (1998) What's wrong with Bonferroni adjustments. BMJ 316: 1236-1238.
59. Coyle JT, (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26: 365-384.
60. Lipska BK, (2004) Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci 29: 282-286.
61. Goldman AL, Pezawas L, Mattay VS, Fischl B, Verchinski BA, et al. (2009) Widespread reductions of cortical thickness in schizophrenia and spectrum disorders and evidence of heritability. Arch Gen Psychiatry 66: 467-477.
62. Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, et al. (2001) The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry 49: 39-46.